Cited 0 times in
P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김주항 | - |
dc.contributor.author | 노성훈 | - |
dc.contributor.author | 유내춘 | - |
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2021-09-28T08:13:42Z | - |
dc.date.available | 2021-09-28T08:13:42Z | - |
dc.date.issued | 1996-12 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/183508 | - |
dc.description.abstract | The expression of p-glycoprotein (p-gp) was evaluated in pre- and post-chemotherapy states after the administration of adriamycin-based chemotherapy in 24 gastric cancer patients. Among them, group A was composed of twelve patients who relapsed after surgery plus adjuvant chemotherapy and group B was composed of another twelve patients who received neoadjuvant chemotherapy plus surgery. Pre-chemotherapy p-gp was evaluated in 18 out of 24 patients (6 patients had no pre-chemotherapy paraffin blocks) and post-chemotherapy p-gp was evaluated from all 24 patients. Pre- and post-chemotherapy p-gp was expressed in 5 of 18 patients (27.8%), and 9 of 24 patients (37.5%), respectively, with immunohistochemical stain using monoclonal antibody JSB-1. No differences of disease-free survivals were observed in Group A based on post-chemotherapy p-gp expression from relapsed lesions. In Group B, there was a higher relapse rate (p = 0.04) and a lower one-year disease-free survival rate (p = 0.04) in post-chemotherapy p-gp positive patients when adjuvant treatment was done with the same regimen as neoadjuvant chemotherapy. In all patients studied, post-chemotherapy p-gp expression correlated with a higher systemic recurrence (p = 0.04). These data suggest that p-gp can be induced by an adriamycin-based chemotherapy in gastric cancer. Thus, we suggest that the prognosis of gastric cancer may be poor if a multidrug resistance (MDR)-related regimen is used in the presence of p-gp after neoadjuvant chemotherapy with an adriamycin-based regimen, even if the initial response is good. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism* | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Doxorubicin / administration & dosage | - |
dc.subject.MESH | Doxorubicin / therapeutic use* | - |
dc.subject.MESH | Drug Resistance | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunohistochemistry | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.subject.MESH | Stomach Neoplasms / drug therapy* | - |
dc.subject.MESH | Stomach Neoplasms / metabolism* | - |
dc.subject.MESH | Stomach Neoplasms / surgery | - |
dc.subject.MESH | Survival Analysis | - |
dc.title | P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Soo Jung Gong | - |
dc.contributor.googleauthor | Nae Choon Yoo | - |
dc.contributor.googleauthor | Sung Hoon Noh | - |
dc.contributor.googleauthor | Joo Hang Kim | - |
dc.contributor.googleauthor | Jae Kyung Roh | - |
dc.contributor.googleauthor | Jin Sik Min | - |
dc.contributor.googleauthor | Byung Soo Kim | - |
dc.contributor.googleauthor | Kim Beom Lee | - |
dc.identifier.doi | 10.3349/ymj.1996.37.6.397 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01281 | - |
dc.contributor.localId | A02457 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 9048492 | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | 김주항 | - |
dc.contributor.affiliatedAuthor | 노성훈 | - |
dc.contributor.affiliatedAuthor | 유내춘 | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.citation.volume | 37 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 397 | - |
dc.citation.endPage | 404 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.37(6) : 397-404, 1996-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.